Metabolic Dysfunction-Associated Steatotic Liver Disease Linked to Risk for Sudden Hearing Loss
By Elana Gotkine HealthDay Reporter

FRIDAY, June 20, 2025 -- Among older adults, metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with increased risk for sudden sensorineural hearing loss (SSNHL), according to a study published in the June issue of Laryngoscope: Investigative Otolaryngology.
Eun Seok Kang, M.D., from the Korea University College of Medicine in Seoul, and colleagues conducted a population-based cohort study using the Korean National Health Insurance Service-Senior cohort involving 189,623 participants aged 65 years or older who were categorized as non-SLD or MASLD. The risk for SSNHL and Meniere disease was examined.
The researchers found that compared with the non-SLD group, participants with MASLD had higher metabolic dysfunction markers, including elevated body mass index, waist circumference, and blood pressure. There were 3,803 SSNHL events in the MASLD group during nine years of follow-up, with an incidence rate of 2.44 per 1,000 person-years. MASLD was associated with a significantly increased risk for SSNHL after inverse probability of treatment weighting (adjusted hazard ratio, 1.05; subdistribution hazard ratio, 1.06).
"This finding serves as an important indicator that reflects the impact of MASLD on disease progression from a prognostic perspective, rather than merely examining the occurrence of the disease itself," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-06-21 06:00
Read more

- FDA Offers Speedier Approvals to Drug Companies Aligning With 'National Priorities'
- New Model Developed for Identifying DVT in Epithelial Ovarian Cancer
- CT Colonography Cost-Effective, Clinically Effective for CRC Screening
- Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease
- Higher Dose of Wegovy Provided Average Weight Loss of 21% in People with Obesity With a Third Achieving 25% or More
- Alcohol-Linked Liver Deaths Rising in Women and Young Adults
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions